Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) CFO William J. Peters sold 60,743 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $51.75, for a total transaction of $3,143,450.25. Following the transaction, the chief financial officer now directly owns 101,360 shares of the company’s stock, valued at approximately $5,245,380. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Amphastar Pharmaceuticals Price Performance
Amphastar Pharmaceuticals stock opened at $50.01 on Friday. The firm has a market cap of $2.41 billion, a PE ratio of 25.65 and a beta of 0.84. Amphastar Pharmaceuticals, Inc. has a 52-week low of $26.76 and a 52-week high of $67.66. The company has a quick ratio of 1.11, a current ratio of 1.53 and a debt-to-equity ratio of 0.83. The company’s 50 day moving average is $57.02 and its two-hundred day moving average is $47.05.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last released its earnings results on Tuesday, August 8th. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. The company had revenue of $145.71 million for the quarter, compared to analyst estimates of $137.20 million. Amphastar Pharmaceuticals had a net margin of 18.85% and a return on equity of 20.12%. On average, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.5 EPS for the current fiscal year.
Institutional Investors Weigh In On Amphastar Pharmaceuticals
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on AMPH. Piper Sandler increased their price objective on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a research report on Wednesday, August 9th. Jefferies Financial Group began coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, July 25th. They set a “buy” rating and a $70.00 price objective for the company. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
- Five stocks we like better than Amphastar Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- MarketBeat Week in Review – 9/4 – 9/8
- Dividend Tax Calculator
- The Best 5 Small Cap AI Companies to Buy Now
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.